Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 1/2021

03.11.2020 | Original Article

MiniPDX-guided postoperative anticancer treatment can effectively prolong the survival of patients with hepatocellular carcinoma

verfasst von: Long Yang, Zheyue Yuan, Yamin Zhang, Zilin Cui, Yang Li, Jiancun Hou, Xiaolong Liu, Zirong Liu, Rui Shi, Qing Tian, Jian Wang, Lianjiang Wang

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

The recurrence rate of hepatocellular carcinoma (HCC) after partial hepatectomy is still high. How to choose the most appropriate anti-tumor drug in the early postoperative period is crucial to improve the prognosis of patients. Recently, MiniPDX has been widely used as a new and reliable preclinical research model capable of predicting the sensitivities of anti-tumor drugs.

Methods

Twenty-eight patients with HCC were selected to use the MiniPDX model to screen the most sensitive anti-tumor drugs from five groups of drug regimens for preventive treatment after partial hepatectomy, and another 42 patients with HCC were selected to be treated with Sorafenib during the same period as the control group. The tumor-free survival rate and overall survival rate were analyzed and compared between these two groups. The relationship between drug sensitivity and biomarkers related to HCC was also analyzed.

Results

Kaplan–Meier survival curve analysis showed that the tumor-free survival (DFS) of patients in the MiniPDX group was significantly longer than that in the control group (median DFS: 25.8 months vs. 18.2 months, P = 0.022, HR 2.19, 95% CI 1.17–4.12). The overall survival (OS) of the patients in the MiniPDX group was also longer than that in the control group (median OS: 29.4 months vs. 23.8 months, P = 0.039, HR 2.37, 95% CI 1.12–5.00). The longest follow-up period was 36 months. The relationship analyzed between the efficacy of the five drugs (Regorafenib, Regorafenib, Lenvatinib, Gemcitabine, 5-FU + Oxaliplatin) and AFP, Ki-67, VEGFR, FGFR, P53, and Nrf2 showed different correlations.

Conclusion

The use of the MiniPDX model to select drugs to guide anti-tumor treatment after partial hepatectomy could effectively prolong the survival of patients with HCC.
Literatur
1.
Zurück zum Zitat Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA: Cancer J Clin 68(6):394–424 Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA: Cancer J Clin 68(6):394–424
2.
Zurück zum Zitat Kulik L, El-Serag HB (2019) Epidemiology and management of hepatocellular carcinoma [J]. Gastroenterology 156(2):477-491 e471PubMed Kulik L, El-Serag HB (2019) Epidemiology and management of hepatocellular carcinoma [J]. Gastroenterology 156(2):477-491 e471PubMed
3.
Zurück zum Zitat Hernandez MC, Bergquist JR, Leiting JL et al (2019) Patient-derived xenografts can be reliably generated from patient clinical biopsy specimens [J]. J Gastrointest Surg: Off J Soc Surg Aliment Tract 23(4):818–824 Hernandez MC, Bergquist JR, Leiting JL et al (2019) Patient-derived xenografts can be reliably generated from patient clinical biopsy specimens [J]. J Gastrointest Surg: Off J Soc Surg Aliment Tract 23(4):818–824
4.
Zurück zum Zitat Malaney P, Nicosia SV, Dave V (2014) One mouse, one patient paradigm: new avatars of personalized cancer therapy [J]. Cancer Lett 344(1):1–12PubMed Malaney P, Nicosia SV, Dave V (2014) One mouse, one patient paradigm: new avatars of personalized cancer therapy [J]. Cancer Lett 344(1):1–12PubMed
5.
Zurück zum Zitat Tentler JJ, Tan AC, Weekes CD et al (2012) Patient-derived tumour xenografts as models for oncology drug development [J]. Nat Rev Clin Oncol 9(6):338–350PubMedPubMedCentral Tentler JJ, Tan AC, Weekes CD et al (2012) Patient-derived tumour xenografts as models for oncology drug development [J]. Nat Rev Clin Oncol 9(6):338–350PubMedPubMedCentral
6.
Zurück zum Zitat Huynh H, Ong R, Soo KC (2012) Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma [J]. Angiogenesis 15(1):59–70PubMed Huynh H, Ong R, Soo KC (2012) Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma [J]. Angiogenesis 15(1):59–70PubMed
7.
Zurück zum Zitat Zhang F, Wang W, Long Y et al (2018) Characterization of drug responses of mini patient-derived xenografts in mice for predicting cancer patient clinical therapeutic response [J]. Cancer Commun 38(1):60 Zhang F, Wang W, Long Y et al (2018) Characterization of drug responses of mini patient-derived xenografts in mice for predicting cancer patient clinical therapeutic response [J]. Cancer Commun 38(1):60
8.
Zurück zum Zitat Zhan M, Yang RM, Wang H et al (2018) Guided chemotherapy based on patient-derived mini-xenograft models improves survival of gallbladder carcinoma patients [J]. Cancer Commun 38(1):48 Zhan M, Yang RM, Wang H et al (2018) Guided chemotherapy based on patient-derived mini-xenograft models improves survival of gallbladder carcinoma patients [J]. Cancer Commun 38(1):48
9.
Zurück zum Zitat Cwinn M, Molinari M (2016) Regional variations in treatment modalities for hepatocellular carcinoma in Canada [J]. Hpb 18:e196–e197 Cwinn M, Molinari M (2016) Regional variations in treatment modalities for hepatocellular carcinoma in Canada [J]. Hpb 18:e196–e197
10.
Zurück zum Zitat Raza A, Sood GK (2014) Hepatocellular carcinoma review: current treatment, and evidence-based medicine [J]. World J Gastroenterol 20(15):4115–4127PubMedPubMedCentral Raza A, Sood GK (2014) Hepatocellular carcinoma review: current treatment, and evidence-based medicine [J]. World J Gastroenterol 20(15):4115–4127PubMedPubMedCentral
11.
Zurück zum Zitat Llovet JM, Bruix J (2008) Molecular targeted therapies in hepatocellular carcinoma [J]. Hepatology 48(4):1312–1327PubMedPubMedCentral Llovet JM, Bruix J (2008) Molecular targeted therapies in hepatocellular carcinoma [J]. Hepatology 48(4):1312–1327PubMedPubMedCentral
12.
Zurück zum Zitat Rimassa L, Santoro A (2009) Sorafenib therapy in advanced hepatocellular carcinoma: the sharp trial [J]. Expert Rev Anticancer Ther 9(6):739–745PubMed Rimassa L, Santoro A (2009) Sorafenib therapy in advanced hepatocellular carcinoma: the sharp trial [J]. Expert Rev Anticancer Ther 9(6):739–745PubMed
13.
Zurück zum Zitat Khandelwal G, Girotti MR, Smowton C et al (2017) Next-generation sequencing analysis and algorithms for pdx and cdx models [J]. Mol Cancer Res: MCR 15(8):1012–1016PubMed Khandelwal G, Girotti MR, Smowton C et al (2017) Next-generation sequencing analysis and algorithms for pdx and cdx models [J]. Mol Cancer Res: MCR 15(8):1012–1016PubMed
14.
Zurück zum Zitat Koga Y, Ochiai A (2019) Systematic review of patient-derived xenograft models for preclinical studies of anti-cancer drugs in solid tumors [J]. Cells 8(5):418PubMedCentral Koga Y, Ochiai A (2019) Systematic review of patient-derived xenograft models for preclinical studies of anti-cancer drugs in solid tumors [J]. Cells 8(5):418PubMedCentral
15.
Zurück zum Zitat Zhao P, Chen H, Wen D et al (2018) Personalized treatment based on mini patient-derived xenografts and wes/rna sequencing in a patient with metastatic duodenal adenocarcinoma [J]. Cancer Commun 38(1):54 Zhao P, Chen H, Wen D et al (2018) Personalized treatment based on mini patient-derived xenografts and wes/rna sequencing in a patient with metastatic duodenal adenocarcinoma [J]. Cancer Commun 38(1):54
16.
Zurück zum Zitat Cheng A-L, Finn RS, Qin S et al (2017) Phase iii trial of lenvatinib (len) vs sorafenib (sor) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uhcc) [J]. J Clin Oncol 35(15_suppl):4001–4001 Cheng A-L, Finn RS, Qin S et al (2017) Phase iii trial of lenvatinib (len) vs sorafenib (sor) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uhcc) [J]. J Clin Oncol 35(15_suppl):4001–4001
17.
Zurück zum Zitat Llovet J, Cheng A, Qin S et al (2019) 6519 efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (hcc): collective results from the phase III sorafenib HCC assessment randomized protocol (sharp) and Asia-Pacific (AP) trials [J]. Eur J Cancer Suppl 7(2):367 Llovet J, Cheng A, Qin S et al (2019) 6519 efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (hcc): collective results from the phase III sorafenib HCC assessment randomized protocol (sharp) and Asia-Pacific (AP) trials [J]. Eur J Cancer Suppl 7(2):367
18.
Zurück zum Zitat Llovet JM (2008) Sorafenib in advanced hepatocellular carcinoma [J]. N Engl J Med 359(23):2498 (author reply 2498–2499) Llovet JM (2008) Sorafenib in advanced hepatocellular carcinoma [J]. N Engl J Med 359(23):2498 (author reply 2498–2499)
19.
Zurück zum Zitat Ikeda M, Mitsunaga S, Ohno I et al (2015) Systemic chemotherapy for advanced hepatocellular carcinoma: Past, present, and future [J]. Diseases 3(4):360–381PubMedPubMedCentral Ikeda M, Mitsunaga S, Ohno I et al (2015) Systemic chemotherapy for advanced hepatocellular carcinoma: Past, present, and future [J]. Diseases 3(4):360–381PubMedPubMedCentral
20.
Zurück zum Zitat Kudo M, Trevisani F, Abou-Alfa GK et al (2016) Hepatocellular carcinoma: therapeutic guidelines and medical treatment [J]. Liver cancer 6(1):16–26PubMedPubMedCentral Kudo M, Trevisani F, Abou-Alfa GK et al (2016) Hepatocellular carcinoma: therapeutic guidelines and medical treatment [J]. Liver cancer 6(1):16–26PubMedPubMedCentral
21.
Zurück zum Zitat Qin S, Cheng Y, Liang J et al (2014) Efficacy and safety of the folfox4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the each study [J]. Oncologist 19(11):1169–1178PubMedPubMedCentral Qin S, Cheng Y, Liang J et al (2014) Efficacy and safety of the folfox4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the each study [J]. Oncologist 19(11):1169–1178PubMedPubMedCentral
22.
Zurück zum Zitat Ikeda M, Morizane C, Ueno M et al (2018) Chemotherapy for hepatocellular carcinoma: current status and future perspectives [J]. Jpn J Clin Oncol 48(2):103–114PubMed Ikeda M, Morizane C, Ueno M et al (2018) Chemotherapy for hepatocellular carcinoma: current status and future perspectives [J]. Jpn J Clin Oncol 48(2):103–114PubMed
23.
Zurück zum Zitat Raghunath A, Sundarraj K, Arfuso F et al (2018) Dysregulation of nrf2 in hepatocellular carcinoma: role in cancer progression and chemoresistance [J]. Cancers 10(12):481PubMedCentral Raghunath A, Sundarraj K, Arfuso F et al (2018) Dysregulation of nrf2 in hepatocellular carcinoma: role in cancer progression and chemoresistance [J]. Cancers 10(12):481PubMedCentral
24.
Zurück zum Zitat He C, Li L, Guan X et al (2017) Mutant p53 gain of function and chemoresistance: the role of mutant p53 in response to clinical chemotherapy [J]. Chemotherapy 62(1):43–53PubMed He C, Li L, Guan X et al (2017) Mutant p53 gain of function and chemoresistance: the role of mutant p53 in response to clinical chemotherapy [J]. Chemotherapy 62(1):43–53PubMed
Metadaten
Titel
MiniPDX-guided postoperative anticancer treatment can effectively prolong the survival of patients with hepatocellular carcinoma
verfasst von
Long Yang
Zheyue Yuan
Yamin Zhang
Zilin Cui
Yang Li
Jiancun Hou
Xiaolong Liu
Zirong Liu
Rui Shi
Qing Tian
Jian Wang
Lianjiang Wang
Publikationsdatum
03.11.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 1/2021
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-020-04182-1

Weitere Artikel der Ausgabe 1/2021

Cancer Chemotherapy and Pharmacology 1/2021 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.